Origin

Developed by the St. Petersburg Institute of Bioregulation and Gerontology as an organ-targeted bioregulator for lung and bronchial tissue, following the Khavinson model.

Mechanism

Proposed to enhance proliferation and differentiation of bronchial and alveolar epithelial cells through epigenetic gene regulation, supporting airway repair and immune defense.

Research summary

Evidence

No English-language peer-reviewed studies indexed in PubMed exist for Chonluten specifically. It's documented only in Russian-language literature and community sources; evidence quality is the family's lowest tier.

Evidence tier: Approved in Russia; research compound — see the methodology note for how this is assessed.

Citations

No specific peer-reviewed citations indexed for this entry — see the research summary above for what evidence does exist.

Reported benefits

claimed bronchial tissue repair
claimed improved respiratory function
claimed reduced respiratory tract inflammation

Dosing protocols reported in the literature & community

These are protocols reported by compounding pharmacies, published trials, or self-experimentation communities — not a prescription. Start low, especially for anything new.

Reported dosing protocols
Route	Reported protocol
Subcutaneous injection	Community reports: 10-20 mg daily or every other day for 10-20 days, repeated seasonally.

Side effects

minimal systemic effects reported
localized injection-site reactions possible

Safety notes

Community & reddit notes (anecdotal — not clinical evidence)

Some self-experimenters use it for chronic respiratory conditions; evidence is testimonial only.